

## Update re: EGM 12 February 2024

Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) refers to its Notice of Meeting for the shareholders meeting to be held in Melbourne on Monday 12 February 2024.

The Company is aware that some RHY shareholders may, in addition to the Company's issued Notice of Meeting (and accompanying proxy form), have received directly from the Requisitioning Shareholders, a form of proxy printed on light blue paper which is pre-completed to vote in favour of their proposed resolution. Shareholders should note there is no obligation to use any pre-completed proxy form.

If you wish to vote by proxy – your proxy should be returned by 12pm AEDST on 10 February 2024 in accordance with the instructions provided on the proxy form.

Directors recommend shareholders should **NOT TAKE ANY ACTION** in respect of the light blue proxy form they may have received from the Requisitioning Shareholders.

The Board confirms its unanimous recommendation to shareholders to vote **AGAINST** the resolution to be considered at the meeting on Monday 12 February 2024.

Shareholders who are executing and returning the GREEN proxy form **DO NOT** need to complete either the light blue or white proxy forms.

Directors recommend that shareholders **IGNORE** the communication from Requisitioning Shareholders.

- ENDS -

### Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:

<b>Mr. Otto Buttula</b> Executive Chairman	<b>Mr. James Barrie</b> Joint Company Secretary	<b>Ms. Andrea Steele</b> General Counsel & Joint Company Secretary
---	--	---

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**Directors**  
Otto Buttula  
Sue MacLeman  
Trevor Lockett  
Louis Panaccio  
Executive Chairman  
Independent Deputy Chair  
Non-Executive Director  
Non-Executive Director

[www.rhythmbio.com](http://www.rhythmbio.com)

**T** +61 3 8256 2880  
**E** [info@rhythmbio.com](mailto:info@rhythmbio.com)

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

**About ColoSTAT<sup>®</sup>**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT<sup>®</sup> Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT<sup>®</sup> Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.